S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
S&P 500   3,225.89 (-3.35%)
DOW   27,960.80 (-3.56%)
QQQ   221.39 (-3.86%)
AAPL   298.18 (-4.75%)
FB   200.72 (-4.50%)
MSFT   170.89 (-4.31%)
GOOGL   1,419.86 (-4.29%)
AMZN   2,009.29 (-4.14%)
CGC   20.30 (-7.22%)
NVDA   273.28 (-7.07%)
BABA   206.16 (-3.02%)
MU   55.01 (-3.47%)
GE   11.86 (-3.18%)
TSLA   833.79 (-7.46%)
AMD   49.12 (-7.81%)
T   38.05 (-1.30%)
ACB   1.55 (-7.19%)
F   7.57 (-4.06%)
NFLX   368.70 (-2.99%)
PRI   126.97 (-4.05%)
BAC   32.73 (-4.74%)
DIS   133.01 (-4.29%)
GILD   72.90 (+4.59%)
Log in

NASDAQ:NTLA - Intellia Therapeutics Stock Price, Forecast & News

$12.58
-0.81 (-6.05 %)
(As of 02/24/2020 04:00 PM ET)
Today's Range
$12.30
Now: $12.58
$13.00
50-Day Range
$11.91
MA: $14.10
$15.58
52-Week Range
$10.26
Now: $12.58
$19.00
Volume772,827 shs
Average Volume630,134 shs
Market Capitalization$614.94 million
P/E RatioN/A
Dividend YieldN/A
Beta2.82
Intellia Therapeutics, Inc, a genome editing company, focuses on the development of therapeutics utilizing a biological tool known as the CRISPR/Cas9 system. The company develops in vivo programs focused on liver diseases, including transthyretin amyloidosis, alpha-1 antitrypsin deficiency, and primary hyperoxaluria. Its ex vivo pipeline includes proprietary programs focused on developing engineered cell therapies to treat various oncological and autoimmune diseases; partnered programs focused on chimeric antigen receptor T cells and hematopoietic stem cells; and acute myeloid leukemia. Read More…

Industry, Sector and Symbol

Industry Diagnostic substances
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:NTLA
CUSIPN/A
Phone857-285-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$30.43 million
Book Value$6.40 per share

Profitability

Net Income$-85,340,000.00
Net Margins-225.54%

Miscellaneous

Employees211
Market Cap$614.94 million
Next Earnings Date2/27/2020 (Confirmed)
OptionableOptionable

Receive NTLA News and Ratings via Email

Sign-up to receive the latest news and ratings for NTLA and its competitors with MarketBeat's FREE daily newsletter.


Intellia Therapeutics (NASDAQ:NTLA) Frequently Asked Questions

What is Intellia Therapeutics' stock symbol?

Intellia Therapeutics trades on the NASDAQ under the ticker symbol "NTLA."

How were Intellia Therapeutics' earnings last quarter?

Intellia Therapeutics Inc (NASDAQ:NTLA) issued its quarterly earnings data on Thursday, October, 31st. The company reported ($0.49) earnings per share for the quarter, beating the Zacks' consensus estimate of ($0.61) by $0.12. The business earned $10.60 million during the quarter, compared to analysts' expectations of $9.17 million. Intellia Therapeutics had a negative return on equity of 33.00% and a negative net margin of 225.54%. The company's revenue was up 43.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.53) earnings per share. View Intellia Therapeutics' Earnings History.

When is Intellia Therapeutics' next earnings date?

Intellia Therapeutics is scheduled to release their next quarterly earnings announcement on Thursday, February 27th 2020. View Earnings Estimates for Intellia Therapeutics.

How can I listen to Intellia Therapeutics' earnings call?

Intellia Therapeutics will be holding an earnings conference call on Thursday, February 27th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for NTLA?

6 analysts have issued twelve-month price objectives for Intellia Therapeutics' shares. Their forecasts range from $16.00 to $57.50. On average, they anticipate Intellia Therapeutics' share price to reach $27.30 in the next year. This suggests a possible upside of 117.0% from the stock's current price. View Analyst Price Targets for Intellia Therapeutics.

What is the consensus analysts' recommendation for Intellia Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Intellia Therapeutics in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Intellia Therapeutics.

Has Intellia Therapeutics been receiving favorable news coverage?

News headlines about NTLA stock have been trending very negative recently, according to InfoTrie Sentiment Analysis. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Intellia Therapeutics earned a news sentiment score of -3.0 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for Intellia Therapeutics.

Who are some of Intellia Therapeutics' key competitors?

What other stocks do shareholders of Intellia Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Intellia Therapeutics investors own include Editas Medicine (EDIT), Crispr Therapeutics (CRSP), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Canopy Growth (CGC), QUALCOMM (QCOM) and Exelixis (EXEL).

Who are Intellia Therapeutics' key executives?

Intellia Therapeutics' management team includes the folowing people:
  • Dr. John M. Leonard, Pres, CEO & Director (Age 62)
  • Mr. Nessan Bermingham Ph.D., Founder & Member of Scientific Advisor Board (Age 46)
  • Mr. José E. Rivera, Exec. VP & Gen. Counsel (Age 53)
  • Ms. Rachel Haurwitz Ph.D., Co-Founder (Age 33)
  • Mr. Andrew May Ph.D., Founder and Member of Scientific Advisor Board

When did Intellia Therapeutics IPO?

(NTLA) raised $85 million in an initial public offering (IPO) on Friday, May 6th 2016. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Intellia Therapeutics' major shareholders?

Intellia Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include ARK Investment Management LLC (17.88%), Nikko Asset Management Americas Inc. (14.69%), Sumitomo Mitsui Trust Holdings Inc. (14.69%), State Street Corp (3.46%), Chevy Chase Trust Holdings Inc. (2.73%) and FMR LLC (1.71%). Company insiders that own Intellia Therapeutics stock include Andrew Schiermeier, Jean Francois Formela and John M Leonard. View Institutional Ownership Trends for Intellia Therapeutics.

Which institutional investors are selling Intellia Therapeutics stock?

NTLA stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, UBS Group AG, Elmwood Wealth Management Inc., Sumitomo Mitsui Trust Holdings Inc., Nikko Asset Management Americas Inc., Goldman Sachs Group Inc., Rafferty Asset Management LLC and Geode Capital Management LLC. View Insider Buying and Selling for Intellia Therapeutics.

Which institutional investors are buying Intellia Therapeutics stock?

NTLA stock was bought by a variety of institutional investors in the last quarter, including FMR LLC, ARK Investment Management LLC, 361 Capital LLC, Chevy Chase Trust Holdings Inc., California Public Employees Retirement System, Jefferies Group LLC, Renaissance Technologies LLC and Jacobs Levy Equity Management Inc.. View Insider Buying and Selling for Intellia Therapeutics.

How do I buy shares of Intellia Therapeutics?

Shares of NTLA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Intellia Therapeutics' stock price today?

One share of NTLA stock can currently be purchased for approximately $12.58.

How big of a company is Intellia Therapeutics?

Intellia Therapeutics has a market capitalization of $614.94 million and generates $30.43 million in revenue each year. The company earns $-85,340,000.00 in net income (profit) each year or ($1.98) on an earnings per share basis. Intellia Therapeutics employs 211 workers across the globe.View Additional Information About Intellia Therapeutics.

What is Intellia Therapeutics' official website?

The official website for Intellia Therapeutics is http://www.intelliatx.com/.

How can I contact Intellia Therapeutics?

Intellia Therapeutics' mailing address is 40 ERIE STREET SUITE 130, CAMBRIDGE MA, 02139. The company can be reached via phone at 857-285-6200 or via email at [email protected]


MarketBeat Community Rating for Intellia Therapeutics (NASDAQ NTLA)

Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  296 (Vote Outperform)
Underperform Votes:  269 (Vote Underperform)
Total Votes:  565
MarketBeat's community ratings are surveys of what our community members think about Intellia Therapeutics and other stocks. Vote "Outperform" if you believe NTLA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NTLA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel